The 11-person team at Codagenix may be tiny, but it has big plans for the company’s new COVID-19 vaccine. The Long Island-based team has developed a vaccine made from a live version of the COVID-19 virus that has been engineered to slow virus replication. Following promising results from a pilot study in hamsters, they are now planning human trials.
“Our vaccine is a single dose intranasal vaccine made with a live attenuated version of the virus,” J. Robert Coleman, Ph.D., MBA, co-founder and chief executive officer of Codagenix, told BioSpace. “Live viruses have a broader and more durable immune response.”
In the immediate future, the Codagenix team has plans for Phase I human clinical trials. To do this, they have teamed up with Open Orphan PLC, a CRO pharmaceutical services company based in Dublin.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).